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Background: In a recent trial, cyclosporine A (CsA) failed to reduce infarct size in acute 
stroke patients treated with intravenous thrombolysis. White matter (WM) and gray mat-
ter (GM) may have distinct vulnerability to ischemia and response to therapy. Using final 
infarct size and lesion growth as endpoints, our objectives were to (1) investigate any 
tissue-specific effect of CsA and (2) compare WM and GM response to thrombolysis.
Materials and methods: We analyzed 84 patients from the randomized and placebo- 
controlled CsA-Stroke trial, who underwent MRI both on admission and at 1 month. 
Lesion growth was defined voxel-wise as infarcted tissue at 1  month with no visible 
lesion on baseline diffusion-weighted imaging. After automatic segmentation of GM/WM, 
final infarct size and lesion growth were compared within the GM and WM.
results: Occlusion level was distal (>M1) in 51% of cases. No significant difference 
in GM/WM proportions was observed within final infarcts between treatment groups 
(P = 0.21). Infarct size within the GM or WM was similar between the CsA and control 
groups [GM: 9.2 (2.4; 22.8) with CsA vs 8.9 (3.7; 28.4) mL with placebo, P = 0.74; 
WM: 9.9 (4.7; 25.4) with CsA vs 14.1 (5.6; 34.1) mL with placebo, P = 0.26]. There was 
no significant effect of CsA on lesion growth in either the GM or WM. Pooling all patients, 
a trend for increased relative lesion growth in WM compared to GM was observed 
[49.0% (14.7; 185.7) vs 43.1% (15.4; 117.1), respectively; P = 0.12].
conclusion: No differential effect of CsA was observed between WM and GM. Pooling 
all patients, a trend toward greater lesion growth in WM was observed.
Keywords: ischemic stroke, thrombolysis, neuroprotection, recanalization, cyclosporin
inTrODUcTiOn
Reperfusion can induce additional injury following prolonged periods of ischemia. CsA may 
limit reperfusion injury by inhibiting several mechanistic pathways: mitochondrial permeability 
transition pore opening, oxidative stress, microglial activation, and apoptosis (1). CsA has reduced 
TaBle 1 | Patients’ baseline characteristics.
Parameter csa control P-value
Age 65.6 ± 11.4 67.8 ± 13.5 0.18
Male, n (%) 23 (56) 19 (44) 0.38
NIHSS, mean (min–max) 12 (4–18) 13 (6–19) 0.24
Time from onset to MRI, min 121 ± 47 111 ± 44 0.09
Delay to thrombolysis, min 161 ± 47 149 ± 46 0.09
DWI lesion (mL), median (IQR) 18.9 (6.7; 44.5) 14.7 (8.0; 39.9) 0.71
Occlusion level, distal/proximal 21/20 22/21 1.0
Recanalization, n (%) 29 (70) 25 (58) 0.12
Results are presented as mean ± SD unless specified otherwise.
CsA, cyclosporine A; NIHSS, National Institutes of Health Stroke Scale; MRI, magnetic 
resonance imaging; DWI, diffusion-weighted imaging; IQR, interquartile range.
FigUre 1 | co-registered masks of acute diffusion-weighted imaging (DWi) lesion, final infarct, and corresponding lesion growth (a) overlaid on 
acute DWi, which were then segmented by the gray matter and white matter probabilistic maps (B).
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infarct size after percutaneous coronary intervention in acute 
myocardial infarction (2). However, in a recent phase 2 trial, 
CsA failed to significantly reduce infarct size in acute stroke 
patients treated with intravenous tissue plasminogen activator 
(tPA) (3).
The failure of neuroprotection trials may in part stem from 
insufficient distinction between white matter (WM) and gray 
matter (GM) (4). Indeed, few studies compared the vulnerability 
of WM and GM during ischemia, or their respective response 
to therapy (5–7). The effects of CsA may differ between these 
two compartments, which exhibit distinct cellular structure, 
metabolic, and hemodynamic requirements.
In this study involving patients treated with intravenous 
thrombolysis (no patient underwent mechanical thrombectomy), 
our objectives were to compare the final infarct size and lesion 
growth within WM and GM in (1) CsA vs placebo-treated 
patients, so as to assess any tissue-specific effect of CsA, and (2) a 
pooled analysis of all patients, to compare WM and GM response 
to ischemia and thrombolysis.
PaTienTs anD MeThODs
Patients
Cyclosporine A-stroke was a multicenter, randomized, single-
blinded phase-II trial that enrolled patients aged 18–85  years 
presenting with an anterior-circulation stroke, a National 
Institutes of Health Stroke Scale score between 6 and 18, and 
who were treated by intravenous tPA within 4.5 h of symptoms 
onset. Patients received either a single intravenous bolus of CsA 
(2.0  mg/kg, Sandimmune, Novartis) or placebo. The primary 
endpoint was infarct size mapped on MRI at 1 month (3). For the 
present study, only patients with complete and assessable MRI at 
baseline and 1 month were included.
Mri Protocol
MRI was the first-line imaging method on admission and inclu-
ded diffusion-weighted imaging (DWI), T2*, fluid-attenuated 
inversion-recovery (FLAIR) and time-of-flight angiography. The 
same protocol was repeated at 1 month.
image analysis
Baseline DWI lesions and final infarcts on FLAIR were outlined 
as previously described (3). WM and GM were individually 
segmented from baseline T2* images using SPM8 (London, UK) 
(6). All baseline and 1-month images were co-registered within 
subjects. Lesion growth was defined as voxels included in the final 
FLAIR lesion, but not in the baseline DWI lesion. WM and GM 
masks were used to assess the volume and proportion of WM and 
GM within the final infarct and lesion growth (Figure 1). Image 
analyses were performed using Matlab (MathWorks, USA).
statistical analyses
Results were described as proportions or median with inter-
quartile range. Comparisons between treatment groups were 
FigUre 2 | infarct size at 1 month according to recanalization status, occlusion level, and treatment groups in the whole brain (a), white matter  
(B), and gray matter (c). Within boxplots: horizontal line indicates the median; lower and upper limits: first and third quartiles; whiskers are placed at 1.5 times the 
interquartile range; crosses indicate the mean, *P = 0.02.
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performed with the Student’s t-test or Wilcoxon ranked-sum test, 
and with the Chi-square or Fisher’s exact test, as appropriate. A 
repeated-measures ANOVA compared the final infarct size and 
lesion growth, globally and within GM and WM. Analyses were 
performed using STATA 13.0 (StataCorp, USA). P-values <0.05 
were considered significant.
resUlTs
From October 2009 to July 2013, 127 patients were enrolled in 
CsA-Stroke. Forty-three patients were excluded from the present 
study because of incomplete/missing baseline MRI or images of 
insufficient quality. Thus, 84 patients were analyzed: 43 and 41 in 
the control and CsA group, respectively. Baseline characteristics 
are summarized in the Table 1. Overall, occlusion level was distal 
(>M1) in 43 patients (51%).
csa vs Placebo
Cyclosporine A did not significantly reduce infarct size at 
1 month compared to placebo [20.6 mL (6.8; 53.8) vs 26.9 mL 
(11.3; 66.3), respectively; P = 0.38], nor lesion growth [9.2 mL 
(2.1; 19.8) vs 10.1 mL (2.7; 33.9), respectively; P = 0.38]. As in 
the main study, CsA-treated patients with a proximal occlusion 
and subsequent recanalization had smaller infarct volumes 
compared to controls [13.1  mL (1.2; 20.3) vs 43.8  mL (12.3; 
106.7), respectively; P =  0.02; Figure  2A], as well as reduced 
lesion growth [3.0 mL (0.3; 9.4) vs 17.1 mL (5.2; 70.9), respec-
tively; P = 0.01]. No significant difference in GM/WM propor-
tions was observed within final infarcts between treatment 
groups [GM/WM (mean ± SD): 46.4 ± 12.6/53.6 ± 12.6% for 
CsA vs 42.6 ± 15.3/57.4 ± 15.3% for placebo; P = 0.21]. Infarct 
size within the GM or WM was similar between the CsA and 
control groups [GM: 9.2  mL (2.4; 22.8) with CsA vs 8.9  mL 
(3.7; 28.4) with placebo, P = 0.74; WM: 9.9 mL (4.7; 25.4) with 
CsA vs 14.1 mL (5.6; 34.1) with placebo, P = 0.26]. Again, CsA 
significantly reduced infarct size in patients with proximal 
occlusion and recanalization, in both the GM [4.3 mL (0.3; 9.4) 
with CsA vs 19.0 mL (6.1; 51.8) in controls; P = 0.048] and WM 
[6.6 mL (0.9; 11.1) in CsA group vs 24.8 mL (5.6; 55.8) in con-
trols; P = 0.01; Figures 2B,C]. There was no significant effect of 
CsA on relative lesion growth compared to placebo in either the 
GM or WM [GM: 33.7% (15.9; 83.4) with CsA vs 60.8% (14.2; 
152.9) in controls, P = 0.35; WM: 32.8% (14.3; 159.0) with CsA 
vs 65.6% (15.2; 208.3) in controls, P = 0.51].
WM vs gM in Pooled analyses
As CsA had overall no impact on imaging endpoints, we pooled 
all patients (CsA and placebo) to further explore any difference 
between GM and WM. Absolute infarct size was similar between 
GM and WM [9.2 mL (2.5; 26.1) vs 11.7 mL (5.5; 29.9), respec-
tively; P = 0.20]. However, final infarcts had greater proportions 
of WM than GM [53.3% (46.9; 64.2) vs 46.7% (35.8; 53.0), 
respectively; P = 0.0005]. Absolute lesion growth was larger in 
WM compared to GM [5.3 mL (1.4; 13.5) vs 3.9 mL (1.1; 10.7), 
respectively; P =  0.012]. A trend for increased relative lesion 
growth in WM compared to GM was observed [49.0% (14.7; 
185.7) vs 43.1% (15.4; 117.1), respectively; P = 0.12].
DiscUssiOn
In this study, we found no differential effect of CsA between WM 
and GM. Tissue-specific measurements showed no benefit of CsA 
in reducing lesion growth or infarct volume. CsA administration 
improved these endpoints in patients with proximal occlusion 
and subsequent recanalization, but to a similar extent in WM and 
GM. The potential benefit of CsA in this subgroup will require 
further evaluation, but our results do not suggest a tissue-specific 
response.
Whether GM and WM have a distinct vulnerability to 
ischemia remains controversial. Higher ischemic thresholds are 
found in GM compared to WM, but this may only reflect the 
inherent gap in metabolism and hemodynamics in these com-
partments (8). Preclinical studies using different animal models 
yielded conflicting results (9, 10). Positron-emission tomography 
and MRI-based clinical reports showed higher proportions of 
penumbral tissue within the WM compared to GM, suggesting 
a greater tolerance to ischemia in the former (5, 6). However, in 
these untreated patients, similar proportions of at-risk WM and 
GM eventually infarcted. In our study, there was a trend toward 
increased lesion growth in WM in a pooled analysis of patients 
treated with intravenous tPA. This may suggest tissue-specific 
responses to ischemia-reperfusion, but needs confirmation in an 
adequately powered study.
Our report has some limitations. Reperfusion, penumbral 
tissue, and its evolution were not monitored, as perfusion-
weighted imaging was not systematically performed. The lack 
of high-resolution T1-weighted imaging may have impaired the 
precision of WM/GM segmentation. The main CsA-Stroke study 
was negative; the present report based on subgroup analyses may 
have an insufficient sample size and thus be underpowered to 
assess the differential effects of CsA in the WM and GM.
In conclusion, in our population of patients with distal or 
proximal occlusions, CsA had no significant effect on lesion 
growth and final infarct size in either the WM or GM. A trend 
toward greater lesion growth in WM was observed when pooling 
all patients.
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